Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications

scientific article published on April 1, 2003

Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1046/J.1365-2036.2003.01545.X
P953full work available at URLhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2036.2003.01545.x
https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2036.2003.01545.x
https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.2003.01545.x
P698PubMed publication ID12694084
P5875ResearchGate publication ID10806058

P2093author name stringU. Ladabaum
P2860cites workAspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysisQ28191273
EuroQol--a new facility for the measurement of health-related quality of lifeQ29547873
Management of the irritable bowel syndromeQ31941893
A general health policy model: update and applicationsQ33717420
Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trialQ33896354
Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysisQ33923878
Lotronex and the FDA: a fatal erosion of integrityQ33948603
Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndromeQ33960506
Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trialsQ33969643
Health-related quality of life and associated psychosocial factors in irritable bowel syndrome: a reviewQ34030004
Costs of care for irritable bowel syndrome patients in a health maintenance organizationQ34103131
Five‐Hundred Life‐Saving Interventions and Their Cost‐EffectivenessQ34299363
Health-related quality of life among persons with irritable bowel syndrome: a systematic reviewQ34657373
How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluationsQ34714134
A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndromeQ39416131
Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patientsQ39434734
Recommendations of the Panel on Cost-effectiveness in Health and MedicineQ41145868
Primer on medical decision analysis: Part 4--Analyzing the model and interpreting the resultsQ41434879
Predicting Quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes StudyQ43406988
The FDA and The Lancet: an exchangeQ43706110
The impact of irritable bowel syndrome on health-related quality of lifeQ46485395
The burden of selected digestive diseases in the United StatesQ50113541
The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factorsQ50126848
Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases.Q53435090
Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome.Q53486440
Primer on Medical Decision Analysis: Part 3—Estimating Probabilities and UtilitiesQ57696073
Utilities and quality-adjusted life yearsQ69463744
Impact of irritable bowel syndrome on quality of lifeQ71835032
Can the standard gamble be used to determine utilities for uncertain health states? An example using postoperative maintenance therapy in Crohn's diseaseQ73363000
American Gastroenterological Association medical position statement: irritable bowel syndromeQ73404058
The FDA and The Lancet: an exchangeQ74367838
Physicians' diagnostic judgments and treatment decisions for acute otitis media in childrenQ74496859
The FDA and The Lancet: an exchangeQ93961585
The FDA and The Lancet: an exchangeQ93961588
The FDA and The Lancet: an exchangeQ93961591
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectalosetronQ416463
pharmacotherapyQ701216
P304page(s)1021-1030
P577publication date2003-04-01
P1433published inAlimentary Pharmacology & TherapeuticsQ4726656
P1476titleSafety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications
P478volume17

Reverse relations

cites work (P2860)
Q383101175-HT7 receptor signaling: improved therapeutic strategy in gut disorders
Q34649076Alosetron and irritable bowel syndrome
Q33274027CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection
Q34489390Costs of irritable bowel syndrome in the UK and US.
Q34618925Gut hormones: emerging role in immune activation and inflammation.
Q45138901Quantitative benefit-risk assessment using only qualitative information on utilities.
Q37944318Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries
Q34317503Serotonin and GI Disorders: An Update on Clinical and Experimental Studies
Q35178813Subjective food hypersensitivity: assessment of enterochromaffin cell markers in blood and gut lavage fluid
Q38032174The chronic gastrointestinal consequences associated with campylobacter